{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:37:00Z","timestamp":1789389420994,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","medical.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.mcna.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:15:18Z","timestamp":1496362518000},"page":"787-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Prevention of Prostate Cancer Morbidity and Mortality"],"prefix":"10.1016","volume":"101","author":[{"given":"Michael J.","family":"Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh H.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2017.03.009_bib1","series-title":"Cancer facts & figures 2016","author":"American Cancer Society","year":"2016"},{"key":"10.1016\/j.mcna.2017.03.009_bib2","unstructured":"Howlander N, Noone AM, Krapcho M, et\u00a0al, editors. SEER cancer statistics review, 1975-2013. National Cancer Institute: Bethesda (MD). Available at: http:\/\/seer.cancer.gov\/csr\/1975_2013\/. Based on November 2015 SEER data submission, posted to the SEER Web site. Accessed April 3, 2017."},{"issue":"2","key":"10.1016\/j.mcna.2017.03.009_bib3","first-page":"195","article-title":"Prostate cancer epidemiology in the United States","volume":"30","author":"Brawley","year":"2012","journal-title":"World J Surg"},{"key":"10.1016\/j.mcna.2017.03.009_bib4","unstructured":"Cancer Research UK. Prostate Cancer Statistics. Available at: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer. Accessed November 29, 2016."},{"key":"10.1016\/j.mcna.2017.03.009_bib5","series-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012","author":"Gu","year":"2014"},{"key":"10.1016\/j.mcna.2017.03.009_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2015.58","article-title":"Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis","volume":"19","author":"Raval","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.mcna.2017.03.009_bib7","first-page":"379","article-title":"Statin drug use is not associated with prostate cancer risk in men who are regularly screened","volume":"192","author":"Platz","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ijc.11466","article-title":"Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis","volume":"107","author":"Bruner","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.mcna.2017.03.009_bib9","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/ijc.29243","article-title":"Family history in the finnish prostate cancer screening trial","volume":"136","author":"Saarimaki","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.mcna.2017.03.009_bib10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bju.13310","article-title":"A\u00a0positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised study of Screening for Prostate Cancer (ERSPC, Aarau)","volume":"117","author":"Randazzo","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.mcna.2017.03.009_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2016.09.026","article-title":"Diet, body size, physical activity and risk of prostate cancer: an umbrella review of the evidence","volume":"69","author":"Markozannes","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.mcna.2017.03.009_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/CMAR.S18503","article-title":"Chemoprevention of prostate cancer with nutrients and supplements","volume":"3","author":"Poppel","year":"2011","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.mcna.2017.03.009_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"The Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2017.03.009_bib14","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2017.03.009_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cncr.27774","article-title":"Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials","volume":"119","author":"Pinsky","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.mcna.2017.03.009_bib18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.mayocp.2016.07.023","article-title":"5-alpha reductase inhibitors and the risk of prostate cancer mortality in men treated for benign prostatic hyperplasia","volume":"91","author":"Wallner","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mcna.2017.03.009_bib19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib20","unstructured":"National Cancer Institute. Prostate-Specific Antigen (PSA) Test. Available at: https:\/\/www.cancer.gov\/types\/prostate\/psa-fact-sheet. Accessed November 30, 2016."},{"key":"10.1016\/j.mcna.2017.03.009_bib21","first-page":"83","article-title":"The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study","volume":"148","author":"Chybowski","year":"1992","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0090-4295(97)00635-3","article-title":"The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population","volume":"51","author":"Stenner","year":"1998","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.mcna.2017.03.009_bib23","doi-asserted-by":"crossref","first-page":"e56030","DOI":"10.1371\/journal.pone.0056030","article-title":"Long distance bicycle riding causes prostate-specific antigen to increase in men aged 50 years and over","volume":"8","author":"Mejak","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mcna.2017.03.009_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2015.11.046","article-title":"Six weeks of fluoroquinolone antibiotic therapy for patients with elevated serum prostate-specific antigen is not clinically beneficial: a randomized controlled clinical trial","volume":"90","author":"Greiman","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.mcna.2017.03.009_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.294.1.66","article-title":"Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0\u00a0ng\/ml or lower","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2017.03.009_bib26","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or\u00a0= 4.0\u00a0ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib27","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","article-title":"Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer","volume":"83","author":"Ankerst","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.mcna.2017.03.009_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","article-title":"Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators","volume":"61","author":"Roobol","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib29","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2017.03.009_bib30","first-page":"1163","article-title":"The prostate health index selectively identifies clinically significant prostate cancer","volume":"193","author":"Loeb","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MOU.0000000000000316","article-title":"Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer","volume":"26","author":"Loeb","year":"2016","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.eururo.2009.07.047","article-title":"Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort","volume":"56","author":"Vickers","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jnci\/djr028","article-title":"An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection","volume":"103","author":"Vickers","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.mcna.2017.03.009_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.urology.2013.09.075","article-title":"A\u00a0commentary on PSA velocity and doubling time for clinical decisions in prostate cancer","volume":"83","author":"Vickers","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.mcna.2017.03.009_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa032975","article-title":"Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy","volume":"351","author":"D'Amico","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.mcna.2017.03.009_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.mcna.2017.03.009_bib38","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMc1515131","article-title":"Reevaluating PSA testing rates in the PLCO Trial","volume":"374","author":"Shoag","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib39","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.2011.41.2767","article-title":"Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"30","author":"Taylor","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2017.03.009_bib40","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2017.03.009_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.eururo.2012.05.068","article-title":"Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"62","author":"Schr\u00f6der","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1078-0432.CCR-15-0941","article-title":"Absolute effect of prostate cancer screening: balance of benefits and harms by center within the European Randomized Study of Prostate Cancer Screening","volume":"22","author":"Auvinen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.mcna.2017.03.009_bib43","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/ijc.24870","article-title":"The effect of study arm on prostate cancer treatment in the large screening trial ERSPC","volume":"126","author":"Wolters","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.mcna.2017.03.009_bib44","first-page":"336","article-title":"Do treatment differences between arms affect the main outcome of ERSPC Rotterdam?","volume":"194","author":"Bokhorst","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jnci\/90.12.925","article-title":"Short-term effects of population-based screening for prostate cancer on health-related quality of life","volume":"90","author":"Essink-Bot","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.mcna.2017.03.009_bib46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib47","doi-asserted-by":"crossref","first-page":"d7894","DOI":"10.1136\/bmj.d7894","article-title":"Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study","volume":"344","author":"Rosario","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2017.03.009_bib48","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1200\/JCO.2012.45.4801","article-title":"Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression","volume":"31","author":"Wade","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2017.03.009_bib49","first-page":"1830","article-title":"Complications after prostate biopsy: data from SEER-Medicare","volume":"186","author":"Loeb","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib51","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib52","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life","volume":"375","author":"Donovan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2013.08.005","article-title":"Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer","volume":"65","author":"Bokhorst","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen\u2013based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib55","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamaoncol.2015.6275","article-title":"Economic analysis of prostate-specific antigen screening and selective treatment strategies","volume":"2","author":"Roth","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.mcna.2017.03.009_bib56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.mcna.2017.03.009_bib57","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3322\/caac.21336","article-title":"Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"66","author":"Smith","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.mcna.2017.03.009_bib58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-158-10-201305210-00633","article-title":"Screening for prostate cancer: a guidance statement from the clinical guidelines committee of the American College of Physicians","volume":"158","author":"Qaseem","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib59","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2012.43.3441","article-title":"Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion","volume":"30","author":"Basch","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2017.03.009_bib60","first-page":"419","article-title":"Early detection of prostate cancer: AUA guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib62","doi-asserted-by":"crossref","first-page":"762","DOI":"10.7326\/0003-4819-155-11-201112060-00375","article-title":"Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force","volume":"155","author":"Chou","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7326\/0003-4819-159-10-201311190-00005","article-title":"Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies","volume":"159","author":"Cho","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib64","first-page":"1286","article-title":"Prostate specific antigen changes as related to the initial prostate specific antigen: data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial","volume":"175","author":"Crawford","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaoncol.2015.5871","article-title":"Prevalence of nonrecommended screening for prostate cancer and breast cancer in the United States: a nationwide survey analysis","volume":"2","author":"Abdollah","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.mcna.2017.03.009_bib66","doi-asserted-by":"crossref","first-page":"c4521","DOI":"10.1136\/bmj.c4521","article-title":"Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study","volume":"341","author":"Vickers","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2017.03.009_bib67","first-page":"1606","article-title":"Prostate specific antigen testing among the elderly\u2013when to stop?","volume":"181","author":"Schaeffer","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib68","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.urology.2016.06.067","article-title":"Contemporary national trends of prostate cancer screening among privately insured men in the United States","volume":"97","author":"Kim","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.mcna.2017.03.009_bib69","first-page":"2037","article-title":"Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves","volume":"152","author":"Catalona","year":"1994","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib70","first-page":"146","article-title":"Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years?","volume":"163","author":"Powell","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib71","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.eururo.2007.11.064","article-title":"Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study","volume":"53","author":"Rosario","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib72","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cncr.28790","article-title":"Multiparametric magnetic resonance imaging outperforms the prostate cancer prevention trial risk calculator in predicting clinically significant prostate cancer","volume":"120","author":"Salami","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.mcna.2017.03.009_bib73","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2014.11.037","article-title":"Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis","volume":"68","author":"Schoots","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib74","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2017.03.009_bib75","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","article-title":"Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer","volume":"33","author":"Tosoian","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2017.03.009_bib76","first-page":"680","article-title":"Active surveillance is an appropriate management strategy for a proportion of men diagnosed with prostate cancer by prostate specific antigen testing","volume":"194","author":"Overholser","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib77","first-page":"626","article-title":"Gleason 6 prostate cancer: translating biology into population health","volume":"194","author":"Eggener","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib78","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/bju.13473","article-title":"Active surveillance for prostate cancer: is it too active?","volume":"118","author":"Ehdaie","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.mcna.2017.03.009_bib79","first-page":"95","article-title":"National trends in the management of low and intermediate risk prostate cancer in the United States","volume":"193","author":"Weiner","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2017.03.009_bib80","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2015.6036","article-title":"Trends in management for patients with localized prostate cancer, 1990-2013","volume":"314","author":"Cooperberg","year":"2015","journal-title":"JAMA"},{"issue":"Suppl Variation","key":"10.1016\/j.mcna.2017.03.009_bib81","doi-asserted-by":"crossref","first-page":"VAR54","DOI":"10.1377\/hlthaff.var.54","article-title":"Policy support for patient-centered care: the need for measurable improvements in decision quality","author":"Sepucha","year":"2004","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.mcna.2017.03.009_bib82","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1370\/afm.1539","article-title":"National evidence on the use of shared decision making in prostate specific antigen screening","volume":"11","author":"Han","year":"2013","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib83","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/archinternmed.2009.262","article-title":"Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS) Study","volume":"169","author":"Hoffman","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib84","unstructured":"The SHARE Approach. Essential Steps of Shared Decision Making: Quick Reference Guide (Workshop Curriculum: Tool 1). 2014. AHRQ Pub. No. 14-0034-1-EF. Available at: www.ahrq.gov\/shareddecisionmaking. Accessed April 3, 2017."},{"key":"10.1016\/j.mcna.2017.03.009_bib85","unstructured":"Six Steps to Shared Decision Making. Healthwise, INC, Web. Available at: http:\/\/cdn-www.informedmedicaldecisions.org\/imdfdocs\/SixStepsSDM_CARD.pdf. Accessed December 3, 2016."},{"issue":"1","key":"10.1016\/j.mcna.2017.03.009_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001431.pub4","article-title":"Decision aids for people facing health treatment or screening decisions","author":"Stacey","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2017.03.009_bib87","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1377\/hlthaff.2015.1376","article-title":"Ten years, forty decision aids, and thousands of patient uses: shared decision making at Massachusetts General Hospital","volume":"35","author":"Sepucha","year":"2016","journal-title":"Health Aff"},{"key":"10.1016\/j.mcna.2017.03.009_bib88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5750\/ijpcm.v5i3.517","article-title":"Patient responses to decision aids in the United States","volume":"5","author":"Wexler","year":"2015","journal-title":"Intl J Pers Cent Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib89","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.amepre.2015.03.002","article-title":"Responses to a decision aid on prostate cancer screening in primary care practices","volume":"49","author":"Barry","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.mcna.2017.03.009_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jama.291.1.15","article-title":"A\u00a0piece of my mind. Winners and losers","volume":"291","author":"Merenstein","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2017.03.009_bib91","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1748-720X.2008.00283.x","article-title":"Reactions of potential jurors to a hypothetical malpractice suit alleging failure to perform a prostate-specific antigen test","volume":"36","author":"Barry","year":"2008","journal-title":"J\u00a0Law Med Ethics"},{"key":"10.1016\/j.mcna.2017.03.009_bib92","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMp1111894","article-title":"One man at a time\u2013resolving the PSA controversy","volume":"365","author":"McNaughton-Collins","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712517300329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712517300329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:18:37Z","timestamp":1719224317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712517300329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0025712517300329"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2017.03.009","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of Prostate Cancer Morbidity and Mortality","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}